Athebio Enters Research Agreement with REGENXBIO

February 4, 2022, Switzerland, Schlieren-Zurich

Athebio AG, an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced that it has entered a research agreement with REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, to develop novel, targeted, adeno-associated virus (AAV) vectors that combine Athebio's proprietary Athebody® DARPin Platform and REGENXBIO’s NAV® Technology Platform.

Under the terms of the agreement, Athebio will provide select Athebody® DARPins from its proprietary library to REGENXBIO, which intends to utilize the DARPins as elements of novel AAV vectors targeted to an undisclosed, cell-specific receptor. REGENXBIO may option the selected Athebody® DARPins for a commercial license for development of potential gene therapy candidates. In exchange, Athebio will receive an undisclosed upfront payment, research funding fees, and has the potential to receive milestones, as well as royalties on net sales.

“As a leader in the field of AAV-mediated gene therapy, REGENXBIO perfectly matches with Athebio's pioneering mindset,” said Patrik Forrer, one of the inventors of the DARPin technology and CEO and Chairman at Athebio. “Our mission is to make our proprietary Athebody® DARPin Platform accessible to our partners, and provide them with tailor-made binding domains and access to our in-depth repeat protein expertise. The small size, excellent intracellular expression, and high specificity make Athebody® DARPins excellent candidates to enable novel, targeted AAV vectors.”

About Athebio

Athebio enables its partners to develop next-generation therapeutics based on leading-edge designed ankyrin repeat protein (DARPin) technology. Rather than building up its own pipeline, Athebio generates tailor-made Athebody® DARPins for its partners. Athebio has brought the DARPin technology to the next level through the development of its proprietary Athebody® DARPin Platform. Athebody® DARPins offer game-changing advantages for generating targeted therapeutics, including high stability, small size, reliable folding, excellent target affinity and specificity, species cross-reactivity, ease of generating multi-specificity, superb developability, and good freedom-to-operate prospects. Athebio enables its partners to rapidly expand their biologics pipelines by providing Athebody® DARPins to unlock therapeutic options not easily accessible with current antibody technologies.

For additional information please contact:

Athebio AG
+41 44 508 08 28
contact@athebio.com
https://www.athebio.com